Efforts in the development of poxvirus-based vaccines to prevent HIV-I have been focused on the SIV model: A protocol designed to obtain preclinical data in the pathogenic SIV251 macaque model is ongoing. The protocol was designed to investigate the modulatory effect of interleukines such as IL-2 and IL-12 on the immunogenicity of a NYVAC- SIV gag, pol, and env vaccine. The adjuvant effect of NYVAC-IL-2 and NYVAC-IL-12, at the time of immunization, was evidenced by changes in the systemic immune responses against viral antigens in vaccinees. Higher cellular immune responses, at the expenses of humoral immune response, were measured in animals exposed to IL-12 at the time of immunization. The immunological modulation induced by IL-2 and IL-12 , however, did not correlate with the ability of the animals to control the acute viremia.The long term outcome of viral challenge demonstrated that,upon intrarectal challenge, half of the animals cleared viral infection and the remaining half become infected as the control animals. Upon intravenous challenge, all the animals became infected but half of them controlled viremia efficiently and did not progress to disease. These cohorts provide a model to study the contribution of different viral subtypes (with different coreceptor usage) in establishing a persistent infection, and disease induction. Because analysis of the classical immunological parameter in the blood of immunized animals cytotoxic lymphocyte activity, T-cell responses upon Ag stimulation, neutralizing Ab)did not provide correlate of immunity, we sought to investigate novel approaches to assess the importance of cell mediated immunity in protection. The lack of availability of syngenetic animals coupled with the difficulty of ablating completely CD8+ cells in vivo, prompted us to investigate a histoculture system developed in Dr. Margolis' laboratory (NICHD/LTPB). Lymph node histocultures from vaccinated/protected and naive animals were tested in vitro for their susceptibility to infection by the viral challenge. All lymph node from vaccinated/protected animals demonstrated resistence to viral infection which could be relieved in some cases by the addition of Ab against the MHC class 1,suggesting a role of cell mediated immunity in protection. The same antibody had no effect on the infectability of lymph node from naive animals. This in vitro histoculture system provides an in vitro tool to study not only immune correlates but also selection of viral genotype/phenotype induced by the host response. Chimpanzee model: A protocol designed to compare the immunogenicity and efficacy of NYVAC and ALVAC HIV vaccines in chimpanzees was initiated in 1995. The animals have been immunized four times with recombinant poxvirus vectors carrying the gag, pol, and env genes. The plan is to challenge these animals intrarectally with the chimpanzee-adapted HIV-IC499 isolate, which is being tested now for infectivity.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Intramural Research (Z01)
Project #
1Z01BC005688-08
Application #
6100850
Study Section
Special Emphasis Panel (BRL)
Project Start
Project End
Budget Start
Budget End
Support Year
8
Fiscal Year
1998
Total Cost
Indirect Cost
Name
National Cancer Institute Division of Basic Sciences
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Gordon, Shari N; Liyanage, Namal P M; Doster, Melvin N et al. (2016) Boosting of ALVAC-SIV Vaccine-Primed Macaques with the CD4-SIVgp120 Fusion Protein Elicits Antibodies to V2 Associated with a Decreased Risk of SIVmac251 Acquisition. J Immunol 197:2726-37
Gordon, Shari N; Doster, Melvin N; Kines, Rhonda C et al. (2014) Antibody to the gp120 V1/V2 loops and CD4+ and CD8+ T cell responses in protection from SIVmac251 vaginal acquisition and persistent viremia. J Immunol 193:6172-83
Gordon, Shari N; Cecchinato, Valentina; Andresen, Vibeke et al. (2011) Smallpox vaccine safety is dependent on T cells and not B cells. J Infect Dis 203:1043-53
Cecchinato, Valentina; Franchini, Genoveffa (2010) Th17 cells in pathogenic simian immunodeficiency virus infection of macaques. Curr Opin HIV AIDS 5:141-5
Herbeuval, Jean-Philippe; Nilsson, Jakob; Boasso, Adriano et al. (2009) HAART reduces death ligand but not death receptors in lymphoid tissue of HIV-infected patients and simian immunodeficiency virus-infected macaques. AIDS 23:35-40
Boasso, Adriano; Vaccari, Monica; Fuchs, Dietmar et al. (2009) Combined effect of antiretroviral therapy and blockade of IDO in SIV-infected rhesus macaques. J Immunol 182:4313-20
Vaccari, Monica; Mattapallil, Joseph; Song, Kaimei et al. (2008) Reduced protection from simian immunodeficiency virus SIVmac251 infection afforded by memory CD8+ T cells induced by vaccination during CD4+ T-cell deficiency. J Virol 82:9629-38
Petrovas, Constantinos; Price, David A; Mattapallil, Joseph et al. (2007) SIV-specific CD8+ T cells express high levels of PD1 and cytokines but have impaired proliferative capacity in acute and chronic SIVmac251 infection. Blood 110:928-36
Hryniewicz, Anna; Price, David A; Moniuszko, Marcin et al. (2007) Interleukin-15 but not interleukin-7 abrogates vaccine-induced decrease in virus level in simian immunodeficiency virus mac251-infected macaques. J Immunol 178:3492-504
Pal, Ranajit; Venzon, David; Santra, Sampa et al. (2006) Systemic immunization with an ALVAC-HIV-1/protein boost vaccine strategy protects rhesus macaques from CD4+ T-cell loss and reduces both systemic and mucosal simian-human immunodeficiency virus SHIVKU2 RNA levels. J Virol 80:3732-42

Showing the most recent 10 out of 27 publications